77 related articles for article (PubMed ID: 7165281)
21. Clinical studies with Corynebacterium parvum.
Mitcheson HD; Castro JE
Dev Biol Stand; 1977 Apr 13-15; 38():509-14. PubMed ID: 344105
[TBL] [Abstract][Full Text] [Related]
22. Immunochemotherapy with Corynebacterium parvum in disseminated cancer.
Israel L
Ann N Y Acad Sci; 1976; 277(00):241-51. PubMed ID: 187100
[No Abstract] [Full Text] [Related]
23. Enzyme-linked immunosorbent assay for the detection of Cryptosporidium parvum IgG in the serum of cats.
Lappin MR; Ungar B; Brown-Hahn B; Cooper CM; Spilker M; Thrall MA; Hill SL; Cheney J; Taton-Allen G
J Parasitol; 1997 Oct; 83(5):957-60. PubMed ID: 9379309
[TBL] [Abstract][Full Text] [Related]
24. In vitro and in vivo effects of Corynebacterium parvum on lymphocyte transformation.
Fisher RA
Dev Biol Stand; 1977 Apr 13-15; 38():461-6. PubMed ID: 608539
[TBL] [Abstract][Full Text] [Related]
25. Requirements for successful immunotherapy and chemoimmunotherapy of a murine model of ovarian cancer.
Vanhaelen CP; Fisher RI
Cancer Res; 1981 Mar; 41(3):980-3. PubMed ID: 7193085
[TBL] [Abstract][Full Text] [Related]
26. Clinical trial with Corynebacterium parvum.
Medenica R; Girard JP; Maurice P
Dev Biol Stand; 1977 Apr 13-15; 38():483-5. PubMed ID: 344103
[TBL] [Abstract][Full Text] [Related]
27. Cell-mediated immunity and serum blocking factors in cancer patients during chemotherapy and immunotherapy.
Noonan FP; Halliday WJ; Wall DR; Clunie GJ
Cancer Res; 1977 Aug; 37(8 Pt 1):2473-80. PubMed ID: 872076
[TBL] [Abstract][Full Text] [Related]
28. B-cell immune responses in HIV positive and HIV negative patients with tuberculosis evaluated with an ELISA using a glycolipid antigen.
Simonney N; Chavanet P; Perronne C; Leportier M; Revol F; Herrmann JL; Lagrange PH
Tuberculosis (Edinb); 2007 Mar; 87(2):109-22. PubMed ID: 17030018
[TBL] [Abstract][Full Text] [Related]
29. Elevated serum levels of a c-erbB-2 oncogene product in oral squamous cell carcinoma patients.
Chen CH; Lin YS; Lin CC; Yang YH; Ho YP; Tsai CC
J Oral Pathol Med; 2004 Nov; 33(10):589-94. PubMed ID: 15482324
[TBL] [Abstract][Full Text] [Related]
30. Anti-dsDNA antibody assay: high specificity and sensitivity with a filtration radioassay in comparison to low specificity with the standard ELISA.
Yu L; Wang J; O'Dell JR; Oates J; Arend WP; Eisenbarth GS
J Rheumatol; 2007 Apr; 34(4):734-9. PubMed ID: 17407230
[TBL] [Abstract][Full Text] [Related]
31. [Dot immuno-gold filtration assay in the diagnosis of suspected paragonimiasis and evaluation of chemotherapeutic effect].
Wang Y; Shi XH; Gan XX
Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2007 Feb; 25(1):65-8. PubMed ID: 17639706
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of cytokines concentration and percentage of survival of rabies virus-infected mice submitted to anti-rabies Vero-cell propagated vaccine and P. acnes.
Megid J; Appolinario CM; Mazzini AM; Almeida MF
Vet Immunol Immunopathol; 2006 Nov; 114(1-2):192-6. PubMed ID: 16930720
[TBL] [Abstract][Full Text] [Related]
33. A novel enzyme-linked immunosorbent assay method for the detection of human neutrophil antigen-2a antibodies.
Bayat B; Werth S; Sachs UJ; Santoso S
Transfusion; 2009 Sep; 49(9):1819-24. PubMed ID: 19497055
[TBL] [Abstract][Full Text] [Related]
34. The effect of intravenous Corynebacterium parvum on gut associated mononuclear phagocytes in normal and tumour bearing rats.
Souter RG; Steer HW
Clin Exp Immunol; 1982 Dec; 50(3):487-94. PubMed ID: 7165995
[TBL] [Abstract][Full Text] [Related]
35. Further observations on the inhibition of tumor growth by Corynebacterium parvum with cyclophosphamide. III. Effect of C. parvum on cyclophosphamide metabolism.
Fisher B; Wolmark N; Rubin H
J Natl Cancer Inst; 1976 Jul; 57(1):225-6. PubMed ID: 1003505
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant intralesional and systemic Corynebacterium parvum immunotherapy for surgically treated head and neck cancer.
Beatty JD; Terz JJ; Brown PW; Lawrence W; Schuller GB; Kaplan AM
Surg Forum; 1978; 29():155-7. PubMed ID: 401122
[No Abstract] [Full Text] [Related]
37. Propionibacterium acnes: interaction with complement and development of an enzyme-linked immunoassay for the detection of antibody.
Burkhart CG; Cantrill J; Butcher CL; Lehmann PF
Int J Dermatol; 1999 Mar; 38(3):200-3. PubMed ID: 10208616
[TBL] [Abstract][Full Text] [Related]
38. Anti-p53 antibodies in serum of smokers and head and neck cancer patients.
Wollenberg B; Jan NV; Pitzke P; Reiter W; Stieber P
Anticancer Res; 1997; 17(1A):413-8. PubMed ID: 9066686
[TBL] [Abstract][Full Text] [Related]
39. Utility of an immunocapture-agglutination test and an enzyme-linked immunosorbent assay test against cytosolic proteins from Brucella melitensis B115 in the diagnosis and follow-up of human acute brucellosis.
Mantecón MA; Gutiérrez P; del Pilar Zarzosa M; Dueñas AI; Solera J; Fernández-Lago L; Vizcaíno N; Almaraz A; Bratos MA; Rodríguez Torres A; Orduña-Domingo A
Diagn Microbiol Infect Dis; 2006 May; 55(1):27-35. PubMed ID: 16500069
[TBL] [Abstract][Full Text] [Related]
40. De novo HCV infection among dialysis patients: a prospective study by HCV core antigen ELISA assay.
Fabrizi F; de Vecchi AF; Como G; Lunghi G; Martin P
Aliment Pharmacol Ther; 2005 Apr; 21(7):861-9. PubMed ID: 15801921
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
